Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.55 |
| ▸ | MMP9 | P14780 | 9/20 | 0.55 |
| ▸ | BMP1 | P13497 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.53 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.53 |
| ▸ | MMP14 | P50281 | 2/20 | 0.53 |
| ▸ | MMP3 | P08254 | 5/20 | 0.53 |
| ▸ | MMP13 | P45452 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323452 | 0.83 | MMP2 (0.73) | MMP2MMP9BMP1CA2MMP1 | |
| SCHEMBL29540673 | 0.83 | MMP2 (0.73) | MMP2MMP9BMP1CA2MMP1 | |
| SCHEMBL6323453 | 0.83 | MMP2 (0.73) | MMP2MMP9BMP1CA2MMP1 | |
| SCHEMBL10619187 | 0.82 | MMP2 (0.62) | MMP2MMP9CA1CA2MMP1 | |
| SCHEMBL14289008 | 0.79 | MMP2 (0.57) | MMP2MMP9CA1CA2MMP1 | |
| SCHEMBL23954123 | 0.79 | MMP2 (0.49) | MMP2MMP9BMP1CA1CA2 | |
| SCHEMBL26464691 | 0.79 | MMP2 (0.49) | MMP2MMP9BMP1CA1CA2 | |
| SCHEMBL7422337 | 0.79 | MMP2 (0.62) | MMP2MMP9BMP1MMP1MMP14 | |
| SCHEMBL7422335 | 0.79 | MMP2 (0.62) | MMP2MMP9BMP1MMP1MMP14 | |
| SCHEMBL15238617 | 0.78 | MMP2 (0.76) | MMP2MMP9BMP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509337-B1 | A method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically | PFIZER INC. | 2003-01-21 | — | — | US | disclosed |
| EP-0821671-B1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS | PFIZER (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5861510-A | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors | PFIZER INC (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0821671-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS | PFIZER INC. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033172-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS | PFIZER INC. (US) | 1996-10-24 | — | — | WO | disclosed |